Close this search box.

Portfolio Valuation Opinions

RNA provides independent portfolio valuation services for funds and their limited partners to assist with mark to market and governance measures for their portfolio investments across the entire spectrum of early-stage to commercial investments.  From discovery stage novel therapies to commercial stage royalties, we understand the ways the market values and assesses assets across the capital life cycle.  This gives our clients and their stakeholders confidence when it comes to the value of their portfolio investments.

Highlighted Case Study

Portfolio Valuation: Life Sciences Investments

Highlighted Case Study

Fairness Opinion: General Partner-led Secondary Transaction

Highlighted Case Study

Fairness Opinion: SPAC Target Company Valuation in Biotech

What Our Clients Say

Sign Up for Periodic Updates

Enter your email address below to receive updates from RNA Advisors.